India’s most-watched pre-IPO name—National Stock Exchange of India Ltd (NSE)—is squarely back in focus. The board declared a ₹35 final dividend for FY25 (May 6, 2025), and the company is awaiting SEBI’s nod on a settlement application tied to legacy “preferential access”/co-location matters—two developments that meaningfully shape the valuation and DRHP runway. Add to that the regulator’s fresh push to formalize pre-IPO trading and curb grey-market risk, and you have a market structure that’s steadily tilting in favor of process-first unlisted participation.
Snapshot: What’s actually changed in 2025
- FY25 performance & dividend: NSE reported Q4 FY25 PAT of ₹2,650 crore and a final dividend of ₹35/share; on a full-year basis, FY25 income rose ~17% and profit surged ~47%. These are verifiable anchors for any valuation conversation.
- Record date chatter: Market trackers widely indicated August 13, 2025 as the record date for the final dividend (NSE is unlisted; verify via company/RTA emails if you’re a registered holder).
- Settlement track to enable IPO: Reuters reports NSE submitted its settlement application on June 20, 2025; earlier coverage pegged the proposal at ₹13.88 bn (~$160m). If approved and court formalities close, SEBI could issue an NOC within months, re-opening the DRHP path.
- Policy tailwinds: SEBI has floated a regulated pre-IPO trading platform to curb grey-market risks and improve price discovery—relevant for serious retail and vendor participation in unlisted counters.
Why this matters: together, cash return discipline (dividend) + regulatory clearance progress (settlement) + market plumbing (pre-IPO framework) strengthen the probability of formal DRHP steps and, in turn, sharpen the valuation anchor for today’s unlisted quotes.
NSE unlisted: where is pricing now?
On UnlistedCorner, our NSE page shows a reference price of ₹2,100 (lot size 100). As in all unlisted deals, this is indicative, varies with block size/counterparty, and serves as a starting point for negotiation—not a firm quote.
Important: In 2024, NSE completed a 4:1 bonus; when comparing historical prices/ratios, normalize figures to ex-bonus terms or you’ll misread valuation trends. Trackers also highlight the August 13, 2025 dividend record date context if you’re transacting near it.
Valuation in 2025: an evidence-based scaffold
Rather than anchoring to GMP chats, triangulate from fundamentals, peers, and cash returns.
1) Profit power as the core anchor
FY25 numbers give you a clean starting point: Income ~₹19,177 cr; PAT ~₹12,188 cr (consolidated). Build a P/E corridor on this base (illustrative, not guidance):
- 25× PAT → ₹3.0 lakh crore equity value
- 30× PAT → ₹3.7 lakh crore
- 40× PAT → ₹4.9 lakh crore
The “right” multiple depends on growth durability (derivatives dominance, clearing, data/licensing), governance comfort, and policy overhang resolution.
2) Peer triangulation (BSE as a listed proxy)
While NSE is structurally different (scale, derivatives leadership), the listed BSE offers a market-implied read on exchange-platform economics. Recent updates highlight sharp revenue and profit growth at BSE, reflecting derivatives traction and operating leverage—useful context when assigning multiples to exchange economics in India.
Inference: strong listed-peer prints tend to support higher structural multiples for the category, but NSE’s multiple should still reflect pending settlement/NOC risk until resolved.
3) Cash returns as a sanity check
A ₹35 dividend on an ex-bonus share base tells you management is willing to share cash even pre-IPO—often a green flag for governance/discipline. Translate this into a dividend yield vs your deal price to cross-check whether you’re paying purely for growth/rerating, or also getting paid while you wait.
4) Supply/float dynamics at listing
When DRHP/RHP details finally emerge, the float size (fresh + OFS) will influence scarcity premia. Larger floats smooth day-one volatility, but can cap exuberant pops. Until then, assume balanced supply and don’t over-pay for “scarcity”.
DRHP prospects: how close are we, really?
- Regulatory gating item: The settlement with SEBI is the keystone. Once accepted and court procedures conclude, media suggests SEBI could issue an NOC within ~3 months—after which DRHP filing/updates can progress on standard timelines. No NOC, no DRHP.
- Company posture: The dividend cadence and AGM timing are consistent with a mature pre-IPO narrative, but are not alone determinative of a near-term listing. Treat them as supporting signals, not proof.
- Market plumbing: If SEBI advances a regulated pre-IPO platform, it could professionalize secondary discovery, reduce friction for holders, and lower the “grey-market discount” historically applied by institutions to unlisted positions.
Base case (our read): Assuming a positive settlement outcome in 2025 and typical drafting/regulatory workflows, the listing window looks more FY26-leaning than calendar-2025—though an earlier outcome is possible if approvals compress. (Treat dates as scenarios, not certainties.)
Exit scenarios for 2025 holders (and would-be buyers)
A) Pre-record-date tidy-up (dividend)
If you already hold, confirm your KYC, bank mandate, and DP details so the dividend lands smoothly. If you’re buying near the record date, remember: beneficial ownership must reflect on the record date, and off-market transfers can take T+1 to a few days depending on counterparty/DP readiness. Missing by a day means missing the dividend. Trackers point to Aug 13, 2025 as the record date—verify via your company/RTA emails.
B) Pre-IPO secondary exit (deal-driven)
Liquidity exists, but is episodic and spread-wide. Expect two-way moves around settlement/DRHP headlines. If you’re long and your entry was rich, partial trims into strength are rational risk management.
C) IPO/listing window
If/when the IPO clears, float size and institutional participation will set the tone. Do not assume a guaranteed pop; the HDB experience in 2025 showed price bands can land below popular unlisted anchors, prompting reset across marquee names. Use that as a discipline reminder rather than a direct comp.
D) Post-listing cadence
Exchanges are earnings-sensitive to volumes, mix, and pricing. The more consistently NSE delivers growth + margin + distributions, the more durable the multiple—and the better your post-listing exit optionality.
Process hygiene (don’t lose money to sloppy execution)
Whether you’re buying or selling NSE unlisted shares:
- Use the depository rails correctly: Transfer off-market via NSDL/CDSL (e-DIS/DIS). Keep invoice/contract note, bank UTR, and depository SMS/email confirmations.
- Pay stamp duty properly: For delivery-based off-market transfers, ₹0.015% of consideration is payable (depositories collect before execution). Gifts/without consideration are typically exempt; follow your DP’s documentation.
- Name/PAN match: Ensure DP account names match your deal docs to avoid rejection/rollback.
- Audit trail: Store everything—this reduces headaches at tax time or during corporate actions.
For dealers/advisors: our Channel Partner (vendor) system
Scale your unlisted practice with:
- In-depth reports on key counters
- Comprehensive dashboard (leads, daily prices, knowledge center, commission tracking)
- Market insights with timely updates
- 3-step onboarding (submit query → verification → go-live)
Get started here: Channel Partner @ UnlistedCorner.
A disciplined 2025 playbook (for buyers and holders)
- Position sizing: Cap single-name exposure (e.g., 5–10% of your unlisted sleeve).
- Three-case valuation: Price using Conservative/Base/Optimistic multiples on FY25 PAT and cross-check vs BSE’s structural economics.
- Scenario timelines: Best-case: settlement accepted + NOC in months → DRHP momentum (FY26 listing plausible). Base-case: admin/macro add time. Slow-case: any adverse legal/policy twist extends runway.
- Process over FOMO: Avoid last-minute buys near record dates without confirmed settlement cycles—you could lose dividend eligibility or overpay.
FAQs
Q1) What is confirmed for FY25?
A: ₹35 final dividend with FY25 results (May 6, 2025). Full-year: income ~₹19,177 cr; PAT ~₹12,188 cr.
Q2) What’s the 2025 dividend record date?
A: Trackers report Aug 13, 2025 (NSE is unlisted; confirm via official company/RTA emails if you’re a holder).
Q3) What could unlock a DRHP?
A: SEBI settlement acceptance + court sign-offs → SEBI NOC → DRHP filing/updates. Reuters pegs the proposal at ₹13.88 bn, with an NOC window of months post-approval.
Q4) How should I think about valuation today?
A: Start with FY25 PAT and apply a P/E corridor (e.g., 25–40×), cross-check with BSE’s earnings momentum and with your expected cash returns (dividends) while you hold.
Q5) How do I transfer shares and pay stamp duty?
A: Use NSDL/CDSL off-market transfer; pay ₹0.015% stamp duty (collected by the depository) before execution. Keep all proofs.
Final word
Bottom line: 2025 brings clearer numbers (strong FY25 prints and a ₹35 dividend), credible regulatory progress (settlement pending), and policy plumbing (a potential pre-IPO platform). Together, they make a pragmatic case for valuation discipline today and a DRHP-to-listing runway skewed to FY26—with upside if approvals move faster. The edge now lies in process-correct execution and scenario-based sizing, not in chasing the loudest whisper.